Dry Eye

The solution was approved by the US Food and Drug Administration in late May 2025.

The expanded clinical suite at Stanton Optical will include keratography, optical coherence tomography, and personalized therapy options for patients with dry eye.

The tool is designed to help with the application of mono-dose, dry eye eye drop vials more easily and accurately.

Ophthalmologists report high satisfaction with lifitegrast for dry eye treatment, noting rapid symptom relief and effective management in diverse patient populations.

A Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025, was assigned by the FDA.

The Topical Sustain Release drop technology was designed to address suboptimal patient adherence and high treatment cost.

The campaign, Eyes Tell the Story: The Impact of Dry Eye, will work to educate the public about dry eye by means of personal stories and survey data.

In addition to Prevent Blindness’ usual free resources, the organization is providing a dedicated webpage, fact sheets, and graphics in both English and Spanish.

Aldeyra resubmits NDA for reproxalap, aiming to address FDA concerns and demonstrate efficacy in treating dry eye disease symptoms.

Both preservative-free, contact lens-friendly drops will be available in most national retailers.

According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.

Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.

The drop has the potential to become the first-ever ocular surface indication for an IG.

Can a drop of perfluorohexyloctane, known to persist in the tear film, influence the precision of keratometry and ultimately affect surgical planning?

When her friend began experiencing dry eye symptoms while undergoing chemotherapy, Katherine Mastrota, OD, MS, FAAO, Dipl ABO, found herself in a unique position to provide specialized advice.

New data for 0.25% reproxalap was announced by Aldeyra Therapeutics, supporting the company’s NDA resubmission for the treatment of dry eye disease.

Participants received either Systane Hydration UD (Alcon, Fort Worth, TX) or saline eye drops (NeilMed, Santa Rosa, CA) 4 times a day for 4 weeks each.

Inflammation is both a cause and consequence of dry eye disease.

Deborah Ristvedt, DO, and Melissa Tawa, OD, FAAO, detail the benefits of interventional glaucoma during their CRU 2025 presentation.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Cecelia Koetting, OD, FAAO, DipABO, and Madeline Yung, MD, detailed the prevalence of the conditions, diagnostic tools, and treatment options.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment.

Healing properties can accelerate and improve outcomes for patients.

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief and targets all 3 layers of the tear film.

An overview of prescription medications available for DED.

Patients reported that Miebo significantly reduced overall symptoms severity at the primary endpoint of change from baseline in the severity of overall dry eye symptoms at day 7.

VEVYE Access for All aims to reduce barriers to dry eye disease therapy via a partnership with PhilRx.